Treatment Sequencing Strategies for R/R CLL: Impact of Prior 1L Therapy

Opinion
Video

Faculty share insights into the overall strategy for managing relapsed/refractory CLL following first-line therapy with venetoclax-based regimens and BTK inhibitors, discussing strategy variations based on prior first-line treatments.

Related Videos
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Jean L. Koff, MD, MS
Hannah Walker-Mimms, MS
Hye Sook Chon, MD, gynecologic oncologist, Gynecologic Oncology Program, Moffitt Cancer Center
Video 16 - "Neoadjuvant Approach in RAI-R-DTC"
Video 15 - "Addressing Unmet Needs and Challenges in RAI-R-DTC Treatment"
David L. Porter, MD, director, Cell Therapy and Transplant, Jodi Fisher Horowitz Professor in Leukemia Care Excellence, Penn Medicine
Changchun Deng, MD, PhD
Vaidehi Mujumdar, MD